Abstract
Bevacizumab- and pemetrexed-based therapies have demonstrated activity in patients with non-small-cell lung cancer (NSCLC) and nonsquamous histologic features. Patients with history of never or light smoking might derive greater benefit from these therapies. The included patients had stage IIIB (malignant pleural effusion) or IV NSCLC with nonsquamous histologic features, adequate organ function, no contraindications to bevacizumab, and no previous cytotoxic therapy. The patients had also never smoked or had smoked ≤ 10 pack years and had quit ≥ 1 year before enrollment. The patients had received 4 cycles of carboplatin (area under the curve, 6), pemetrexed 500 mg/m(2), and bevacizumab 15 mg/kg. Patients without disease progression initiated maintenance therapy with pemetrexed and bevacizumab. A single-arm phase II trial with the primary endpoint of progression-free survival (PFS) was performed. The secondary endpoints were the objective response rate (ORR), overall survival (OS), and toxicity. From March 2010 to November 2013, 38 eligible patients were enrolled and treated in the trial. The most common histologic type was adenocarcinoma (97%). Most of the patients were women (66%) and never smokers (63%). The median PFS was 12...Continue Reading
References
Oct 16, 2002·Oncogene·Gerd P PfeiferPierre Hainaut
Jun 5, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Y K TanA Seow
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vincent A MillerRobert T Heelan
Aug 11, 2004·Chest·Luke T NordquistGerold Bepler
Apr 25, 2006·Cancer·Anne S TsaoWaun Ki Hong
May 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chee-Keong TohEng-Huat Tan
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Feb 28, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Jenifer L MarksWilliam Pao
May 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio Vittorio ScagliottiDavid Gandara
May 13, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jyoti D PatelPhilip D Bonomi
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Sep 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Charles M RudinJonathan M Samet
Dec 24, 2009·Cancer·Yelena Y JanjigianGregory J Riely
Jan 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne E DahlbergDavid H Johnson
Dec 2, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Giorgio ScagliottiChandra P Belani
Feb 22, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·D Ross CamidgeRobert C Doebele
May 31, 2011·Lancet·Roy S HerbstJohn Hainsworth
Jun 7, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Jeong-Ok LeeYung-Jue Bang
Jul 1, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Jong-Mu SunMyung-Ju Ahn
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pasi A JänneVincent A Miller
Aug 14, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A T ShawG V Scagliotti
Aug 18, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C ChargariE Deutsch
Jul 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luis G Paz-AresCesare Gridelli
Jul 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fabrice BarlesiHarry J M Groen
Sep 17, 2013·PloS One·Ting WangLi Li Luo
Sep 2, 2014·The Lancet Oncology·Takashi SetoNobuyuki Yamamoto
Citations
Feb 21, 2019·Molecular Cancer·Jing YangXiawei Wei
Dec 12, 2018·BMC Cancer·Yasuhiro TsutaniMorihito Okada
Jun 16, 2017·Scientific Reports·Hui TanDengfeng Cheng
Apr 2, 2020·Central European Journal of Public Health·František Perlík
Jul 22, 2018·International Journal of Clinical Oncology·Taichi TakashinaUNKNOWN Hokkaido Lung Cancer Clinical Study Group
Oct 24, 2020·Current Genomics·Daniel Humberto PozzaVamsidhar Velcheti